Navigation Links
China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
Date:2/27/2012

he first nine months, processing fees and storage fees grew by 7.1% and 43.6%, respectively. Gross profit for the first nine months of fiscal 2012 increased 15.9% to RMB217.4 million ($34.5 million) from RMB187.5 million in the prior year period. Operating income increased by 14.4% to RMB100.0 million ($15.9 million). Net income attributable to shareholders rose to RMB102.7 million ($16.3 million), reflecting contributions from the discrete tax benefits from the Beijing and Guangdong subsidiaries. Basic and diluted earnings per share attributable to ordinary shares were both RMB1.39 ($0.22).

Ms. Zheng further commented, "Under the 'One License Per Region' policy, CCBC continues to be the largest and strongest player in the industry and strives to deepen market penetration in the Beijing and Guangdong markets, which together cover an addressable market of 1.2 million newborns per annum. We are actively pursuing the commercialization process within the affluent Zhejiang market, which will enable us to add an additional 500,000 newborns per annum to our addressable market. Our enhanced strength in cash flow generating capability will not only enable us to reward our shareholders in the long run, but also facilitate our plans to further expand in the Asia Pacific region."

Conference Call The Company will host a conference call at 8:00 a.m. ET on Tuesday, February 28, 2012 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session. Interested parties may access the audio webcast through the Company's IR website at http://ir.chinacordbloodcorp.com. A replay of the webcast will be accessible two hours after the presentation and available for three weeks at the same URL link above. Listeners may also access the call by dialing 1-718-354-1231 or 1-866-519-4004 for US callers or +852-2475-0994 for Hong Kong callers, access c
'/>"/>

SOURCE China Cord Blood Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
3. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
4. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
5. China Biologic Products Announces Second Quarter 2008 Results Conference Call
6. China Medicine Announces Strong Second Quarter 2008 Results
7. China Biologic Products Establishes Governance and Nominating Committee and Compensation Committee
8. China Bio Energy Holdings Group Reports Second Quarter 2008 Financial Results
9. China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease
10. China-Biotics, Inc. Reports First Quarter 2009 Financial Results
11. China Biologic Products Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... , May 5, 2015  A group of ... of the Coma Research Institute, a non-profit organization dedicated ... and families suffering from disorders of consciousness.  ... http://photos.prnewswire.com/prnh/20150504/213779LOGO   ... of consciousness, in which no voluntary actions can be ...
(Date:5/5/2015)... 05, 2015 Research and Markets ... the "Clinical Laboratory, Molecular Diagnostics and Genomic ... 2019 - Global Version" report to their ... the area of molecular diagnostics and pharmacogenics hold ... world market that is moving out of the ...
(Date:5/5/2015)...  Orexigen Therapeutics, Inc. (Nasdaq: OREX ) will ... Friday, May 8 before the market opens. The announcement ... call at 8:30 a.m. Eastern Time (5:30 a.m. Pacific ... by phone by calling (800) 708-4540 (domestic) or (847) ... accessed live on the Investors section of the Orexigen ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 GEA ... last week as recipients of the INTERPHEX Exhibitor ... recognition of their Portable, Continuous, Miniature and Modular ... a small footprint, continuous processing equipment, smart control ... process API powders and inactive ingredients into bulk ...
Breaking Biology Technology:Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 3Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 4Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 5Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2GEA Pharma Systems, G-CON Manufacturing and Pfizer Consortium Receives Best Technology Innovation Award at INTERPHEX 2015 2GEA Pharma Systems, G-CON Manufacturing and Pfizer Consortium Receives Best Technology Innovation Award at INTERPHEX 2015 3
... Drug Offers Potential Treatment ... to Americans Suffering from IBS-C, BETHESDA, Md., Sept. 17 ... the supplemental,New Drug Application (sNDA) for lubiprostone (8 mcg, oral ... with,constipation (IBS-C) has been accepted for review by the U.S. ...
... 17 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ) ... President, will present an overview of the Company,s ... Annual Investment Conference,in San Francisco. Dr. Henderson,s presentation ... am PT. Dr. Henderson,s presentation will be ...
... Tissue Provides Building-Block Cells for Muscle, Bone, ... ... BioLife Solutions,Inc. (OTC Bulletin Board: BLFS), a leading developer ... tissues, and organs, today announced that privately held Tissue,Regeneration Therapeutics ...
Cached Biology Technology:FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 2FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 3FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 4FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 5Keryx Biopharmaceuticals to Present at Bank of America Investment Conference 2BioLife Solutions' CryoStor(TM) Adopted by Tissue Regeneration Therapeutics for Preservation Protocol for New, Non-Embryonic Source of Stem Cells 2BioLife Solutions' CryoStor(TM) Adopted by Tissue Regeneration Therapeutics for Preservation Protocol for New, Non-Embryonic Source of Stem Cells 3
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
(Date:3/31/2015)... , March 31, 2015  Elephant Talk Communications Corp. ... global provider of Software Defined Network Architecture (ET Software ... total revenue of approximately $20.4 million for the year ... $19.5 million for the year ended December 31, 2013. ... the Company had completed its multi-year transition away from ...
(Date:3/24/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ... Iris Recognition Market 2015-2019" report to their offering. ... market to grow at a CAGR of 23.5 percent ... the present scenario and the growth prospects of the ... calculate the market size, the report considers the revenue ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... doesn,t bed down with theatre, much less mate with ... explored in the recent production Heuschrecken [The Locusts] developed ... asks Arizona State University,s Manfred Laubichler and Gitta Honegger ... of the journal Science . "Scientists have ...
... WASHINGTON, Jan. 28, 2010 The U.S. Department ... the release of new satellite images depicting agricultural land ... crop year. The images, referred to as cropland data ... rotation patterns, land use changes, water resources and carbon ...
... The Genetics Society of America (GSA) is pleased ... distinguished service to the field of genetics. These ... the genetics community. The individuals who receive these ... recognition of the exceptional value of their work to ...
Cached Biology News:Scientists and cast of thousands swarm stage in Europe 2Scientists and cast of thousands swarm stage in Europe 3The Genetics Society of America announces its 2010 award recipients 2The Genetics Society of America announces its 2010 award recipients 3
Edited by D. Patel (1994) Comprehensive data on gel electrophoresis of proteins, nucleic acids, nucleoproteins and carbohydrates....
...
... Silver Staining Kit, 1. Select from ... and peptides on denaturing, native, and ... reproducibility with precast gels, buffer strips, ... to that of radioisotopes with ready-to-use ...
Human HAPLN1 MAb (Clone 316119) Protein Family: Hyaluronan (HA) & HA Binding Proteins, Proteoglycan Regulators...
Biology Products: